分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

Cathepsin B Mediates HDAC Inhibitor-Induced Epithelial-Mesenchymal Transition in Lung Cancer Cells

Xiaorui Wan, Huanchen Wu, Jie Xue, Haidong Xu, Jing Wang, Jiani Huang, Weilong Wu, Ruihan Zhang, Zhongqin Liang, Zhenyu Xuan, Yan Wang

Journal:EUROPEAN JOURNAL OF PHARMACOLOGY

IF:5.7

DOI:10.1016/j.ejphar.2026.178565

PMID:

Published:2026-01-17

research field:分子生物学细胞生物学皮肤科免疫学

Abstract

This study investigates the mechanisms by which histone deacetylase (HDAC) inhibitors induce epithelial-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC), focusing on the role of Cathepsin B. Lung cancer cell lines A549 and H1975 were treated with HDAC inhibitors SAHA and SB939, and various assays were conducted to assess cell viability, apoptosis, migration, invasion, and cytoskeletal changes. The expression of EMT-related proteins and Cathepsin B was analyzed using western blotting, immunofluorescence, and quantitative PCR. The results demonstrated that HDAC inhibitors reduced cell viability and increased apoptosis while promoting EMT phenotypes, enhancing migration and invasion. Cathepsin B was identified as a key mediator of the HDAC inhibitor-induced EMT, which it promotes by interacting with and upregulating the transcription factor Slug. These findings suggest that Cathepsin B is a crucial factor in HDAC inhibitor-induced EMT in NSCLC, indicating that targeting this enzyme may provide a novel therapeutic strategy to counteract invasiveness in lung cancer.

本文使用的Yeasen产品

购物车
客服
转染试用